Video

Jason R. Gotlib on JAK Inhibitors for the Treatment of Myelofibrosis

Author(s):

Jason R. Gotlib

Jason R. Gotlib discusses JAK inhibitors for the treatment of patients with myelofibrosis.

Jason R. Gotlib, associate professor of Medicine (Hematology) at Stanford University Medical Center, discusses JAK inhibitors for the treatment of patients with myelofibrosis.

Gotlib discusses whether next-generation JAK inhibitors should be used after resistance to Jakafi (ruxolitinib) or in the frontline setting. Gotlib also provided an overview of drugs that are being studied in combination with these agents.

Gotlib is a 2015 MPN Hero in the category of Commitment to the Individual and is also an international leader in MPN research.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Anne M. Reb is a nurse practitioner with City of Hope.
Image of woman with brown hair.
Image of man with black hair.
Image of bald man.
Image of man.
Image of Kumar.
Related Content
Jane Biehl is a 12-year survivor of a very rare form of blood cancer, known as myelodysplastic syndrome (MDS). Catch up on all of Jane’s blogs here!
April 24th 2025

Taking Charge of My Care and Advocacy Following a Cancer Diagnosis

Jane Biehl Ph.D.
After a long battle with illness and seeking many specialists, I emphasize the need to self-advocate for ongoing care following my cancer diagnosis.
Cancer Horizons podcast logo
January 8th 2024

FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis

Alex Biese Brielle Benyon
The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.
An AI model may help identify patients with myelofibrosis at high risk of early death after transplant, according to an expert: © stock.adobe.com.
April 18th 2025

AI Tool May Better Predict Transplant Risk in Myelofibrosis

Spencer Feldman
An AI model may help identify patients with myelofibrosis at high risk of early death after transplant, according to an expert.
LeVar Burton Helping the MPN Community Through Advocacy and Storytelling
December 16th 2021

LeVar Burton Helping the MPN Community Through Advocacy and Storytelling

Jamie Cesanek Darlene Dobkowski, MA
On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
April 11th 2025

What Role May ctDNA Have in Melanoma Management?

Dr. Michael K. Wong
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
Illustration of woman.
April 8th 2025

Sometimes Cancer is a (Welcome) Distraction

Jane Biehl Ph.D.
In an upside-down, topsy-turvy world, cancer can be a distraction for us.